These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 7152076

  • 1. Protective effects of buflomedil against exercise-induced reductions in regional erythrocyte deformability of patients with peripheral arterial disease.
    Guerrini M, Acciavatti A, Materazzi M, Rossi C, Del Bigo C, Forconi S, Di Perri T.
    J Int Med Res; 1982; 10(6):387-93. PubMed ID: 7152076
    [No Abstract] [Full Text] [Related]

  • 2. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S, Pieragalli D, Acciavatti A, Del Bigo C, Galigani C, Ralli L, Guerrini M, Di Perri T.
    J Int Med Res; 1984; 12(3):188-92. PubMed ID: 6734922
    [No Abstract] [Full Text] [Related]

  • 3. Effect of buflomedil chlorhydrate on local oxygen delivery in peripheral vascular disease.
    Mannarino E, Pasqualini L, Maragoni G, Orlandi U.
    Angiology; 1989 Jun; 40(6):559-62. PubMed ID: 2719340
    [Abstract] [Full Text] [Related]

  • 4. Metabolic effects of buflomedil hydrochloride.
    Briguglio F, Di Marco V, Circosta C, Padovano I, Ragusa S, Saija A, Briguglio E.
    J Int Med Res; 1985 Jun; 13(3):131-58. PubMed ID: 2989026
    [No Abstract] [Full Text] [Related]

  • 5. Haemodynamic and haemorheological effects of buflomedil in patients with peripheral occlusive arterial disease.
    Perego MA, Sergio G, Espureo M, Francisci A, Artale F.
    Curr Med Res Opin; 1982 Jun; 8(3):178-87. PubMed ID: 7128189
    [Abstract] [Full Text] [Related]

  • 6. Improvements in the rheologic properties of blood induced by medium-term treatment with buflomedil in diabetic patients.
    Coccheri S, Palareti G, Poggi M, Tricarico MG.
    J Int Med Res; 1982 Jun; 10(6):394-8. PubMed ID: 7152077
    [No Abstract] [Full Text] [Related]

  • 7. [Protective effect of buflomedil hydrochloride on erythrocyte sickling. In vitro study].
    Briguglio F, Briguglio E, Di Marco V.
    Minerva Med; 1986 Feb 28; 77(7-8):249-62. PubMed ID: 3951731
    [Abstract] [Full Text] [Related]

  • 8. [Digital blood flow in peripheral vascular diseases. Action of drugs: buflomedil].
    Frausini G, Rotatori P, Gaggi S, Barone A, Pupita F.
    Minerva Cardioangiol; 1988 Jun 28; 36(6):319-22. PubMed ID: 3211330
    [No Abstract] [Full Text] [Related]

  • 9. [Acute affect of buflomedil hydrochloride (bufedil) on transcutaneously measured oxygen pressures in patients with peripheral arterial occlusive disease].
    Lemke R, Klaus D.
    Vasa; 1984 Jun 28; 13(2):171-4. PubMed ID: 6741240
    [No Abstract] [Full Text] [Related]

  • 10. [Metabolic changes in muscle and blood caused by ergometric stress in chronic arterial occlusive disease (I)].
    Nissen P, Alexander K.
    Vasa; 1985 Jun 28; 14(1):25-30. PubMed ID: 3976273
    [No Abstract] [Full Text] [Related]

  • 11. An experimental overview of a new vasoactive drug: buflomedil HCl.
    Dubourg A, Scamuffa RF.
    Angiology; 1981 Oct 28; 32(10):663-75. PubMed ID: 7034590
    [Abstract] [Full Text] [Related]

  • 12. [Decrease of blood viscosity induced by buflomedil in healthy volunteers].
    Craveri A, Tornaghi G, Paganardi L, Ranieri R, Di Bella M.
    Minerva Cardioangiol; 1988 Oct 28; 36(7-8):357-60. PubMed ID: 3211334
    [No Abstract] [Full Text] [Related]

  • 13. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA.
    Int Angiol; 2001 Dec 28; 20(4):337-44. PubMed ID: 11782701
    [Abstract] [Full Text] [Related]

  • 14. [Clinical value of hemorrheology in peripheral arterial occlusive diseases].
    Sciannameo F, Francucci M, Cao PG, Giustozzi G, Valentini M, Tockner M, Sassano L, Grasselli A.
    Ric Clin Lab; 1983 Dec 28; 13 Suppl 3():417-22. PubMed ID: 6673023
    [Abstract] [Full Text] [Related]

  • 15. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
    Sunder-Plassmann L, Gandolfo AM, Utz C.
    MMW Munch Med Wochenschr; 1984 Mar 02; 126(9):247-8. PubMed ID: 6425678
    [No Abstract] [Full Text] [Related]

  • 16. [Exertion-induced metabolic changes in arterial occlusive diseases with obstruction at different levels].
    Maass U, Grote R, Alexander K.
    Vasa; 1986 Mar 02; 15(3):212-6. PubMed ID: 3094266
    [No Abstract] [Full Text] [Related]

  • 17. [Hemorrheologic aspects in relation to the physiopathology and clinical aspects of peripheral occlusive arteriopathy].
    Perego MA, Sergio G, Artale F.
    Ric Clin Lab; 1981 Mar 02; 11 Suppl 1():281-91. PubMed ID: 7188115
    [No Abstract] [Full Text] [Related]

  • 18. tcpO2, arterial blood flow and lactate/pyruvate modifications induced by a single dose of naftidrofuryl IV during stage III lower-limb arteriopathies.
    Pointel JP, Thomas C, Mosnier M, Percebois G, Debry G.
    Angiology; 1986 Sep 02; 37(9):647-53. PubMed ID: 3767072
    [Abstract] [Full Text] [Related]

  • 19. [The relation between erythrocyte filterability and platelet aggregation (in vitro studies in normal subjects and those with vascular disease before and after isotonic exercise)].
    Guerrini M, Vittoria A, Pieragalli D, Acciavatti A, Del Bigo C, Martelli G, Franchi M, Messa G, Galigani C, Di Perri T.
    Ric Clin Lab; 1983 Sep 02; 13 Suppl 3():309-14. PubMed ID: 6231712
    [Abstract] [Full Text] [Related]

  • 20. Experience with buflomedil in peripheral arterial occlusive disease.
    Balas P, Pagratis N.
    Angiology; 1981 Oct 02; 32(10):679-85. PubMed ID: 7325404
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.